Company Performance - Viking Therapeutics, Inc. (VKTX) closed at $24.09, reflecting a -2.92% change from the previous day's closing price, underperforming the S&P 500 which gained 0.47% [1] - The stock has decreased by 38.02% over the past month, contrasting with the Medical sector's gain of 5.49% and the S&P 500's gain of 2.32% [1] Earnings Expectations - The upcoming earnings disclosure is anticipated to show an EPS of -$0.71, representing a 222.73% decline compared to the same quarter last year [2] - Full-year Zacks Consensus Estimates predict earnings of -$2.48 per share and revenue of $0 million, indicating year-over-year changes of -145.54% and 0%, respectively [2] Analyst Estimates - Recent changes in analyst estimates for Viking Therapeutics suggest a shifting business landscape, with positive changes indicating a favorable outlook on business health and profitability [3] - The Zacks Rank system, which incorporates estimate changes, currently ranks Viking Therapeutics at 4 (Sell), following a 2.44% decline in the Zacks Consensus EPS estimate over the past month [5] Industry Context - The Medical - Biomedical and Genetics industry, which includes Viking Therapeutics, has a Zacks Industry Rank of 95, placing it in the top 39% of over 250 industries [6] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [6]